Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

Summary

In a 68-week, double-blind phase 3 trial (n=1206), once-weekly cagrilintide-semaglutide led to a mean −13.7% weight change vs −3.4% with placebo and markedly higher proportions achieving weight-loss thresholds. Additionally, 73.5% of patients reached HbA1c ≤6.5% vs 15.9% on placebo. Gastrointestinal adverse events were more frequent with CagriSema but were mostly mild to moderate and transient.

Key Findings

• Mean weight change at 68 weeks: −13.7% with cagrilintide-semaglutide vs −3.4% with placebo (P<0.001).
• Higher proportions achieved ≥5%, ≥10%, ≥15%, and ≥20% weight loss with CagriSema (all P<0.001).
• HbA1c ≤6.5% achieved in 73.5% with CagriSema vs 15.9% with placebo.
• Gastrointestinal adverse events occurred in 72.5% vs 34.4% (mostly mild/moderate, transient).

Clinical Implications

CagriSema could become a powerful weekly option for people with T2D and obesity, enabling clinically meaningful weight loss and improved glycemic targets. Clinicians should monitor GI tolerability and consider dose-escalation strategies.

Limitations

• Increased gastrointestinal adverse events in the active arm requiring tolerability management
• Duration limited to 68 weeks; no active-comparator arm; industry-funded

Future Directions

Head-to-head comparisons with other anti-obesity agents, long-term cardiometabolic outcomes, and pragmatic studies on adherence and GI tolerability are warranted.